Abstract: The invention relates to a synchronous machine which is excited by permanent magnets and has a stator (2) and a rotor (1) which rotates adjacent to the stator (2) about a longitudinal axis (3). The rotor (1) comprises a number of surface magnets which are disposed along the circumference of the rotor (1). The surface magnets are designed as Halbach arrays (4), each of which comprises tangential segments (PM1, PM4, PM5, PM8), in which the magnetisation direction (M) is oriented predominantly in the circumferential direction, and normal segments (PM2, PM3, PM6, PM7), in which the magnetisation direction (M) is oriented predominantly in the radial direction or counter to the radial direction, and in the field of the stator (2) the tangential segments (PM1, PM14, PM5, PM8) are subjected to a radially inwardly directed force (?Fn) and the normal segments (PM2, PM3, PM6, PM7) are subjected to a radially outwardly directed force (+Fn).

Abstract: The electric machine includes a rotor and a stator, wherein the stator has stator coils, each with a coil core. The electric machine additionally includes an error-recovery device configured to change a magnetic flux coupling of coil cores with one another by a flux conducting element. The hybrid electric aircraft is a hybrid electric airplane, in particular, and the hybrid electric aircraft has such an electric machine.

Abstract: An X-ray source device includes an anode to generate X-rays; a drive to rotate the anode about an anode central axis, the drive including a stator and a first rotor, and the first rotor being rotationally fixed relative to the anode; and a cooling facility to cool at least one of the anode and the drive using a coolant. The drive includes a second rotor to circulate the coolant.

Abstract: The disclosure relates to a redundant electric machine for driving a propulsion means with increased operational safety. The machine may include two systems, with each system including a stator winding system and a rotor assigned thereto with permanent magnets, wherein the rotors are fastened on a common shaft for driving the propulsion means. If a fault occurs in one of the stator winding systems, the rotor, which continues to rotate, has to be prevented from inducing electric voltages in the stator winding system because this may lead to a fire in the machine. A demagnetization apparatus is therefore provided which, in a targeted manner, demagnetizes the permanent magnets of the rotor assigned to the faulty stator winding system such that the inducing of electric voltages is prevented.

Abstract: The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

Abstract: An X-ray source device includes an anode to generate X-rays; a drive to rotate the anode about an anode central axis, the drive including a stator and a first rotor, and the first rotor being rotationally fixed relative to the anode; and a cooling facility to cool at least one of the anode and the drive using a coolant. The drive includes a second rotor to circulate the coolant.

Abstract: The electric machine includes a rotor and a stator, wherein the stator has stator coils, each with a coil core. The electric machine additionally includes an error-recovery device configured to change a magnetic flux coupling of coil cores with one another by a flux conducting element. The hybrid electric aircraft is a hybrid electric airplane, in particular, and the hybrid electric aircraft has such an electric machine.

Abstract: The disclosure relates to a redundant electric machine for driving a propulsion means with increased operational safety. The machine may include two systems, with each system including a stator winding system and a rotor assigned thereto with permanent magnets, wherein the rotors are fastened on a common shaft for driving the propulsion means. If a fault occurs in one of the stator winding systems, the rotor, which continues to rotate, has to be prevented from inducing electric voltages in the stator winding system because this may lead to a fire in the machine. A demagnetization apparatus is therefore provided which, in a targeted manner, demagnetizes the permanent magnets of the rotor assigned to the faulty stator winding system such that the inducing of electric voltages is prevented.

Abstract: The machine assembly includes a plurality of electric machines, wherein rotors and/or stators of the electric machines are mechanically coupled to one another. The electric machine serves, in particular, to constitute a machine assembly and includes a housing for a rotor and/or stator, wherein the housing has a respective first and second mechanical connection element, wherein first and second mechanical connection elements correspond to one another. The vehicle may be an electric and/or hybrid-electric vehicle. The vehicle has a machine assembly and/or at least one electric machine, in particular a drive having the machine assembly or the electric machine.

Abstract: An electric motor equipped with a transmission unit in the form of a planetary gear transmission is provided. The planetary gear transmission has a sun gear, planetary gears, and a ring gear, which are coupled to one another via corresponding toothings. The sun gear is coupled directly to a shaft of the electric motor and is fastened thereto. The planetary gears or axles thereof are retained on a bearing plate of the electric motor. The ring gear is rotatably mounted on the housing of the electric motor or is fastened to the housing of the electric motor. A common feature is that parts of the transmission are retained on the housing of the electric motor and not on a separate housing or another component of the transmission unit.

Abstract: The present disclosure relates to methods for treating Hidradenitis Suppurativa (HS) using IL-17 antagonists, e. g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating HS patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.

Abstract: The invention relates to an in particular redundant electrical machine for driving a propulsion means with improved protection against failure. The machine includes for example two submachines consisting in each case of a stator winding system and a rotor, wherein the two rotors are arranged on a common shaft in a rotationally fixed manner, by way of which shaft the propulsion means is ultimately set in motion. Also provided is a movement device which has the effect, in the case of a fault in one of the stator winding systems, that the air gap between the stator winding system in question and the associated rotor is increased for the corresponding faulty submachine such that the electromagnetic interaction between these components is suppressed.

Abstract: The invention relates to an electric motor equipped with a transmission unit, for example in the form of a planetary gear transmission. The planetary gear transmission has a sun gear, a plurality of planetary gears, and a ring gear, which are coupled to one another via corresponding toothings The sun gear is coupled directly to a shaft of the electric motor and is fastened thereto. The planetary gears or the axles thereof are retained on a bearing plate of the electric motor, such that the transmission unit does not have to provide any additional components for this purpose. In one embodiment of the planetary gear transmission, the ring gear is rotatably mounted on the housing of the electric motor. In an alternative embodiment, the ring gear is fastened to the housing of the electric motor.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Improved methods and compositions for safe and effective treatment of telangiectasia or a symptom associated with telangiectasia in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).

Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.

Abstract: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.